AIM： To assess the use of capecitabine-based therapy and associated complication rates in patients with gastroesophageal cancer （GEC） in a real-world treat- ment setting. METHODS： Patients with claims between 2004...AIM： To assess the use of capecitabine-based therapy and associated complication rates in patients with gastroesophageal cancer （GEC） in a real-world treat- ment setting. METHODS： Patients with claims between 2004 and 2005 were identified from the Thomson Reuters MarketScan databases. Capecitabine regimens were compared with 5-fluorouracU （5-FU） and other chemotherapy regimens, and were stratified by treatment setting. RESULTS： We identified 1013 patients with GEC： approximately half had treatment initiated with a 5-FU regimen, whereas 11% had therapy initiated with a capecitabine regimen. The mean capecitabine dose overall was 2382 ± 1118 mg/d, and capecitabine was used as monotherapy more often than in combination. Overall, 5-FU regimens were the most common treat- ment option in neoadjuvant and adjuvant settings, while other non-capecitabine regimens were used more widely in first- and second-line settings. The overall unadjusted complication rate for capecitabine regimens was about half of that seen with 5-FU regimens. In multivariate analyses, capecitabine recipients had a 51% （95% CI： 26%-81%） lower risk of developing any complication than 5-FU recipients did. The risk of developing bone marrow, constitutional, gastrointestinal tract, infectious, or skin complications was lower with capecitabine therapy than with 5-FU.CONCLUSION： Capecitabine appeared to have a favorable side effect profile compared with 5-FU, which indicates that it may be a treatment option for GEC.展开更多
The ultimate goal of cancer genetics is to exploit molecular changes in a cancer to design tumor specific therapies.Ma et al.in their recent paper in Cell Research used an elegant strategy,a CRISPR-Cas9 synthetic leth...The ultimate goal of cancer genetics is to exploit molecular changes in a cancer to design tumor specific therapies.Ma et al.in their recent paper in Cell Research used an elegant strategy,a CRISPR-Cas9 synthetic lethal knockout screen,to identify vulnerabilities in MEN1 deficient tu-mor cells in cell culture.They then successfully translated these results into the development of candidate gene targets for possible drug ther-apy.MEN1 deficiency occurs in sporadic neuroendocrine tumors,and germline mutations in the gene are the basis for cancer predisposition in the human multiple endocrine neoplasia(MEN1)syndrome 1,2.Such pa-tients are at high risk for the development of a variety of neuroendocrine neoplasms,including pancreatic neuroendocrine carcinomas,which are often not amenable for curative surgical resection and account for the mortality of MEN1 patients 3.展开更多
文摘AIM： To assess the use of capecitabine-based therapy and associated complication rates in patients with gastroesophageal cancer （GEC） in a real-world treat- ment setting. METHODS： Patients with claims between 2004 and 2005 were identified from the Thomson Reuters MarketScan databases. Capecitabine regimens were compared with 5-fluorouracU （5-FU） and other chemotherapy regimens, and were stratified by treatment setting. RESULTS： We identified 1013 patients with GEC： approximately half had treatment initiated with a 5-FU regimen, whereas 11% had therapy initiated with a capecitabine regimen. The mean capecitabine dose overall was 2382 ± 1118 mg/d, and capecitabine was used as monotherapy more often than in combination. Overall, 5-FU regimens were the most common treat- ment option in neoadjuvant and adjuvant settings, while other non-capecitabine regimens were used more widely in first- and second-line settings. The overall unadjusted complication rate for capecitabine regimens was about half of that seen with 5-FU regimens. In multivariate analyses, capecitabine recipients had a 51% （95% CI： 26%-81%） lower risk of developing any complication than 5-FU recipients did. The risk of developing bone marrow, constitutional, gastrointestinal tract, infectious, or skin complications was lower with capecitabine therapy than with 5-FU.CONCLUSION： Capecitabine appeared to have a favorable side effect profile compared with 5-FU, which indicates that it may be a treatment option for GEC.
文摘The ultimate goal of cancer genetics is to exploit molecular changes in a cancer to design tumor specific therapies.Ma et al.in their recent paper in Cell Research used an elegant strategy,a CRISPR-Cas9 synthetic lethal knockout screen,to identify vulnerabilities in MEN1 deficient tu-mor cells in cell culture.They then successfully translated these results into the development of candidate gene targets for possible drug ther-apy.MEN1 deficiency occurs in sporadic neuroendocrine tumors,and germline mutations in the gene are the basis for cancer predisposition in the human multiple endocrine neoplasia(MEN1)syndrome 1,2.Such pa-tients are at high risk for the development of a variety of neuroendocrine neoplasms,including pancreatic neuroendocrine carcinomas,which are often not amenable for curative surgical resection and account for the mortality of MEN1 patients 3.
